A retrospective cohort study on the impact of gonadotropin dose on embryo quality and pregnancy outcome: identification of optimal dose range - Scorecard - MDSpire
Advertisement
A retrospective cohort study on the impact of gonadotropin dose on embryo quality and pregnancy outcome: identification of optimal dose range
Clinical Scorecard: Evaluating the Influence of Gonadotropin Dosage on Embryo Quality and Pregnancy Success: A Retrospective Cohort Analysis to Determine the Ideal Dosage Range
At a Glance
Category
Detail
Condition
Infertility
Key Mechanisms
Gonadotropin dosage influences embryo quality and pregnancy outcomes during controlled ovarian stimulation.
Target Population
Patients undergoing in vitro fertilization (IVF) with antagonist regimen fertility treatment.
Care Setting
Reproductive medicine center
Key Highlights
Higher rates of excellent embryos and clinical pregnancy in lower Gn dose groups.
Gn dose above certain thresholds negatively impacts blastocyst formation and live birth rates.
Regression analysis identifies total Gn as an independent risk factor for pregnancy outcomes.
Guideline-Based Recommendations
Diagnosis
Patients diagnosed with tubal infertility and normal ovarian reserve function.
Management
Controlled ovarian stimulation using gonadotropin with careful dosage adjustments.
Monitoring & Follow-up
Monitor embryo quality and pregnancy outcomes based on Gn dosage.
Risks
High Gn doses may increase the risk of ovarian hyperstimulation syndrome and negatively affect egg quality.
Patient & Prescribing Data
1854 patients treated for IVF between January 2019 and October 2024.
Gn doses categorized into quartiles, with lower doses associated with better outcomes.
Clinical Best Practices
Adjust Gn dosage to optimize embryo quality and pregnancy outcomes.
Utilize antagonist regimen for ovulation induction based on individual patient factors.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
